Document and Entity Information - shares |
3 Months Ended | |
|---|---|---|
Mar. 31, 2020 |
Jun. 12, 2020 |
|
| Document And Entity Information | ||
| Entity Registrant Name | INTERPACE BIOSCIENCES, INC. | |
| Entity Central Index Key | 0001054102 | |
| Document Type | 10-Q/A | |
| Document Period End Date | Mar. 31, 2020 | |
| Amendment Flag | true | |
| Amendment Description | On March 25, 2020, the U.S. Securities and Exchange Commission (the "SEC") issued an order Release No. 34-88465 (the "Order") pursuant to its authority under Section 36 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") granting exemptions from certain provisions of that Act and the rules thereunder related to the reporting and proxy delivery requirements for certain public companies. Interpace Biosciences, Inc. (the "Company") is filing this Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 in reliance on the Order, permitting a delay in filing due to circumstances related to COVID-19. The Company filed, on May 15, 2020, a Current Report on Form 8-K (the "May 15th 8-K") indicating its intention to rely on the Order. As stated in the May 15th 8-K, the Company required additional time to finalize this report due to circumstances related to COVID-19, the disease caused by the coronavirus. The effects of COVID-19 have limited the abilities of the Company's employees to conduct normal business activities. This, in turn, delayed the Company's ability to prepare this report. This Amendment No. 1 on Form 10-Q/A (this Amendment) amends the Company's Report on Form 10-Q for the quarter ended March 31, 2020, as amended, (the "Original Filing") and is being filed to show the impact in such quarter of intangible asset amortization and impairment expense for its Barrett's and Thyroid assets which began in 2014. Subsequent to the issuance of its consolidated financial statements for the year ended December 31, 2019 and the quarters ended March 31, 2020 and June 30, 2020, the Company determined that amortization should have commenced upon acquisition of those assets as opposed to the Company's previously disclosed policy of beginning asset amortization when the product was launched and generating revenue. The impact of the additional amortization expense for each of the quarters ended March 31, 2020 and March 31, 2019 was approximately $0.1 million. The impact of the other immaterial adjustments for the quarters ended March 31, 2020 and March 31, 2019 was $0.1 million in expense and $0.2 million in a credit to expense, respectively A description of these adjustments and a summary showing their effect on the restated consolidated statements of operations is provided in Note 1 to the consolidated financial statements. In addition to the errors described above, the restated financial statements also include adjustments to correct certain other immaterial errors, including previously unrecorded immaterial adjustments identified in audits of prior years' financial statements. The Company is filing this report in order to amend certain information in Items 1, 2 and 4 of Part I to reflect the restatement of the March 31, 2020 and 2019 unaudited interim consolidated statements of operations and Notes 1,3,5 and 9 to the consolidated financial statements attached hereto solely to the extent necessary to reflect the adjustments described herein; and the principal executive officer and principal financial officer certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. Except for the foregoing items, no other information in the Original Filing is revised by this Amendment. | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business Flag | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 4,036,595 | |
| Document Fiscal Period Focus | Q1 | |
| Document Fiscal Year Focus | 2020 |